PI3

(redirected from PI3 Kinase)
AcronymDefinition
PI3PI3 Kinase
PI3Protease Inhibitor 3 (gene)
PI3Para Influenza 3 (virus)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Based on the present and previous results on radiation resistance pathways, it is proposed that PI3 kinase Mec1 acted as a nodal point in the regulatory network of transduction events elicited by direct and indirect oxidative effects of ionizing radiation.
* One of the main drivers in the expansion of the AML market will be the launch of premium-priced targeted therapies (FLT3 kinase inhibitors, PI3 kinase inhibitor and reformulations of chemotherapy drugs).
Cells were treated for 1 hour with 1 nM NRG-1,100 nM of the PI3 kinase inhibitor wortmannin, or 1 nM NRG-1 and 100 nM wortmannin combined, n = 3.
These Reports highlights therapeutic targets and their mode of action; for instance Breast Cancer targets: PI3 Kinase inhibitors, Human Epidermal Growth Factor Receptor 4 (HER-4/ERBB4) inhibitors, etc.
Fudala and colleagues (16) also established that Fc[gamma]RIIa mediates antiapoptotic activity of the complexes, and found that the key components of the Fc[gamma]RIIa signaling pathway--Src, Syk, PI3 kinase, and ERK--may be involved in the complexes' neutrophil apoptosis regulation.
For example, inhibition of PI3 kinase by an inhibitor blocked insulin-induced 3T3-L1 adipocyte differentiation [3, 4].
Dysregulation of the pathway is complicated by crosstalk between mTOR and other signalling pathways like AKT and PI3 kinase. Though mTOR pathway dysregulation manifests into various pathological states, it is not the only candidate responsible for the effect.
The results showed that a molecular signalling pathway know as the 'PI3 Kinase pathway' is activated as soon as five minutes after the epithelial cells encounter C.
Insulin modulates several metabolic pathways through a cascade of steps by activating PI3 kinase and when its action is insufficient these steps do not take place (Anandharajan et al.
Matching patients who have cancers with activating mutations in the phosphoinositide 3-kinase (PI3 kinase) signaling pathway to phase I protocols testing PI3 kinase inhibitors has improved response rates and survival (6).
Activation of the PI3 kinase pathway can induce skeletal muscle hypertrophy, defined as an increase in skeletal muscle mass.
In the three other types of breast cancer, a series of biochemical reactions known as the PI3 kinase pathway is overstimulated because of mutations in genes involved at different steps of the process.